The aim of this study is to report the clinic-pathological profile of 1Supervised and Final approval of children with TBM and their treatment outcome. the version to be published Methodology: A retrospective observational study was conducted in the 2-4Substantial contributions to the Pediatrics Department over 6 months period. Medical records of children conception or design of the work, admitted with TBM from November 2017 to May 2018 were reviewed for data twhoerakcoqruriesivtiisoinng,5,6itDcrraitfticinagllythfoer collection. Data regarding clinical presentation, laboratory investigations were important intellectual content, recorded. Patients were treated with a standard ATT regimen, and their 7,8analysis, or interpretation of outcome was noted. The study was approved by hospital ethics committee. data for the work, Data was entered in SPSS for statistical analysis. Funding Source: None Results: Females were predominant 39 (55.7%) and age ranged from 4 months Conflict of Interest: None to 13 years in this study. Only 28 (42.0%) children were fully vaccinated and had Received: Dec 17, 2021 BCG scar presence. Most TBM cases were of stage II 24 (42.8%) or stage III 29 Accepted: July 21, 2022 (42.8%). The frequent symptoms were fever 61 (87.1%), rigidity/irritability 35 Address of Correspondent (50.0%), and seizures 26 (37.1%). WBCs count in CSF was found below 500 in 64 Prof. Maqbool Hussain (91.4%) children. There were 55 (78.5%) children with lymphocytosis and 14 Professor & Head of Pediatrics, (20.0%) with polymorph nuclear cells. A CT scan was suggestive of TBM in 51 Children Hospital, PIMS (72.8%) children. Only 21 (30.0%) cases had a complete recovery whereas 17 drmaqboolhussain@gmail.com (24.2%) recovered with sequelae and 10 (14.2%) deaths were noted. Conclusion: TBM presents with a poor clinical and pathological state in the advanced stage of the disease, and the therapy outcome is also non-satisfactory with high mortality and sequelae posing constant challenges.